ReviewInternal and emergency medicine2008
Low-molecular-weight heparin in patients with chronic renal insufficiency.
Review in Internal and emergency medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.European journal of clinical pharmacology · 2012Pooled it
- A Survey on Anticoagulation Practices in Patients with Chronic Kidney Disease in Saudi Arabia.Journal of clinical medicine · 2026Article
- Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation.Journal of clinical medicine · 2025Article
- Baseline predictors of in-hospital mortality after acute traumatic spinal cord injury: data from a level I trauma center.Scientific reports · 2022Article
- 3-O sulfation of heparin leads to hepatotropism and longer circulatory half-life.Thrombosis research · 2018Article
- Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis.Journal of thoracic disease · 2015Article
- Cancer-associated thrombosis: an overview.Clinical Medicine Insights. Oncology · 2014Review
- Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Drugs & aging · 2011Review
- How to handle low-molecular-weight heparins in patients with decreased renal function: an open issue.Internal and emergency medicine · 2008Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-molecular-weight heparin (LMWH) has largely replaced unfractionated heparin for the treatment of venous thromboembolism. The predictable anticoagulant effect of LMWH is seen across almost all patient populations, with few exceptions. However, because LMWH is primarily eliminated through the kidneys, patients with renal insufficiency are at risk of LMWH accumulation and bleeding complications. The risk of LMWH accumulation and bleeding is dependent on several factors including the degree of renal insufficiency, dose and type of LMWH. These risks are greatest when therapeutic doses of LMWH are used in patients with creatinine clearance less than 30 ml/min. Prophylactic dose LMWH does not appear to be associated with an increased bleeding risk, but has not been evaluated in large trials. LMWHs with a higher molecular weight may be less prone to accumulation and bleeding. LMWH must be used carefully in patients with renal insufficiency, particularly in those with severe renal impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.